Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > REGULATORY
REGULATORY
- Use of MID-NET in PMS Could Promote Comparisons of One’s Own Products with Other Treatments: FPMAJ Official
June 7, 2016
- MHLW to Place 2-Year Grace Period on Mandatory Barcode Labeling by March 2021 for Companies with “Special Circumstances”
June 6, 2016
- 141 Trials of Nucleic Acid Drugs Underway Worldwide, but 70% Being Conducted by US Companies: JPO Survey
June 6, 2016
- Cabinet OKs New Growth Strategy, Basic Economic and Fiscal Policy
June 3, 2016
- “Minor Discrepancies” between Marketing Approval and Actual Manufacturing Processes Found for about 70% of Products: MHLW
June 3, 2016
- Clinical Research Bill Didn’t Clear Diet, Now under Continued Review
June 2, 2016
- Tax Hike Delay Kills Feared Price Cuts in 2017, but Concerns Linger over Expensive Drug Debate
June 2, 2016
- MHLW Proposes Discontinuing Supply of Human Thrombin Products
June 2, 2016
- MHLW Expects Stable Supply of Kaketsuken’s Blood Products Despite Earthquake Damage: Official
June 2, 2016
- Bisphosphonate Labels to Add Osteonecrosis of External Auditory Canal in ADR List
June 1, 2016
- Boehringer’s Reversal Agent for Pradaxa Becomes 1st Drug Subject to Japan’s Compassionate Use Scheme
June 1, 2016
- MHLW Initiates Discussions on Palliative Care for CV Diseases
June 1, 2016
- MHLW Drug Review Panel Shelves ASKA’s Hepatic Encephalopathy Drug
May 31, 2016
- Lawmakers Eye Genomic Medicine Bill to Fuel Diagnostics Development
May 31, 2016
- AMED to Support Drug Discovery Research Using Existing Drugs as “Tool Compounds”
May 31, 2016
- G7 Leaders Vow to Consider New Incentives to Spur AMR R&D
May 30, 2016
- MHLW Panel OKs Sanofi’s PCSK9 Inhibitor on Equal Footing with Repatha
May 30, 2016
- AZ’s Ticagrelor, Boehringer’s Triple Combo Fail to Clear MHLW Advisory Panel
May 30, 2016
- AMED to Allocate 820 Million Yen for Measures against Antimicrobial Resistance
May 27, 2016
- Clinical Research Bill Unlikely to Clear Diet in Current Session
May 27, 2016
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…